Skip to content

OABI

OmniAb, Inc.

NASDAQ · Healthcare · Biotechnology · US

$5.18
+0.58%
Ask drillr

Year over year

Reported trailing growth

Revenue
+90.5%
EBITDA
+54.2%
EBIT
+32.6%
EPS
+41.4%
Free cash flow
+106.8%
Operating cash flow
+107.7%

Forward estimates

Based on analyst estimates

Revenue
-24.7%
EBITDA
-77.0%
EPS
-16.6%

Three-year CAGR

Revenue
-31.9%
EBITDA
+6.9%
EBIT
+4.0%
Net income
-4.4%
EPS
+6.6%
Free cash flow
+10.9%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026